**Pymarceuticals Analysis**

**Aaron Halbert**

Overall out of the 9 drugs tested alongside the placebo only 2 of them seem to be effective at reducing tumor volume over the trial period, Capomulin and Ramicane. The remaining drugs showed an increase in Tumor volume over the trial. 3 of the drugs showed greater growth than the Placebo group.

While looking at the Survival During Treatment graph it is seen that once again Capomulin and Ramicane are more effective at keeping the subjects alive. Both drugs having rates above 80% and the remaining drugs below 60%. Propriva performing the worst at about 25%. Once again we see that the Placebo is performing in the middle of the remaining 7 drugs.

As stated earlier once one removes Capomulin and Ramicane, the Placebo’s performance is roughly as effective as any of the remaining drugs in the study. While much more study is needed before anyone can give a definitive answer as to the long term effectiveness of these drugs , if pressed for a decision on where to focus further research funds I would suggest Capomulin and Ramicane at this point given the current data.